|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.20 ILa | -1.38% |
|
-8.76% | -47.70% |
| 06-02 | Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab | CI |
| 05-20 | Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -1.38% | -8.76% | -23.80% | -45.98% | -47.70% | -68.78% | -95.23% | -98.59% | -99.35% | 5.6M | |
| +0.34% | +1.09% | +1.54% | +7.06% | -6.95% | -10.80% | -5.05% | -22.87% | +210.42% | 43.13B | |
| +1.88% | +3.49% | +9.30% | +71.43% | +107.97% | +313.71% | +563.40% | +403.04% | - | 34.65B | |
| +0.51% | +1.44% | -12.31% | -0.97% | -10.45% | +5.65% | +46.34% | -18.18% | +750.70% | 30.03B | |
| -0.53% | -6.35% | -0.49% | +0.07% | -25.88% | +7.67% | -21.79% | -31.52% | +161.37% | 28B | |
| -1.06% | -2.60% | -6.69% | -12.41% | -2.25% | +9.08% | +21.51% | -26.93% | +152.41% | 24.45B | |
| +0.27% | +3.64% | -6.33% | - | - | - | - | - | - | 14.34B | |
| -2.00% | -3.31% | +4.44% | -1.08% | -19.52% | +46.45% | +101.25% | +147.26% | - | 13.14B | |
| +1.54% | +0.16% | +1.44% | +4.48% | +1.73% | +6.65% | +8.89% | -32.18% | +94.22% | 12.53B | |
| +2.95% | +2.96% | +0.78% | +7.57% | -3.74% | +102.15% | +84.83% | +102.04% | +237.10% | 12.25B | |
| -1.56% | -2.53% | +23.30% | +43.48% | -20.98% | -2.25% | -36.66% | -32.18% | +115.32% | 11.18B | |
| -4.87% | -7.32% | +5.00% | -1.32% | -17.88% | -26.14% | - | - | - | 9.13B | |
| -2.93% | +0.25% | +16.80% | +8.29% | -4.25% | +14.22% | -26.40% | -49.03% | +102.57% | 9.07B | |
| -2.14% | -3.74% | +13.18% | +14.83% | -9.05% | +23.10% | -11.14% | -50.16% | +117.74% | 8.91B | |
| +6.07% | +12.64% | -13.27% | +1.32% | +1.10% | +615.79% | +1,627.45% | +1.20% | - | 7.87B | |
| +0.88% | +0.82% | -18.98% | -15.22% | -28.74% | +1,556.37% | +440.30% | +193.33% | +1,440.39% | 7.77B | |
| -0.65% | -0.72% | +4.48% | -6.95% | -22.38% | -25.27% | -27.52% | -30.62% | +45.75% | 7.64B | |
| +2.56% | +3.64% | +24.93% | +65.91% | +64.31% | +57.13% | +36.71% | +89.67% | +6.82% | 7.5B | |
| +9.26% | +16.06% | +25.92% | +29.08% | +27.67% | +114.60% | +323.99% | +123.29% | - | 7.44B | |
| +1.73% | +2.03% | +15.68% | +16.44% | +31.37% | +115.03% | +316.63% | +164.38% | - | 7.26B | |
| Average | +0.57% | +1.53% | +3.25% | +9.79% | +0.76% | +150.23% | +185.97% | +46.22% | +256.57% | 14.82B | |
| Weighted average by Cap. | +0.49% | +1.64% | +2.32% | +13.95% | +7.38% | +113.12% | +158.88% | +60.41% | +290.50% |
- Stock Market
- Stocks
- EVGN Stock
- Sector Evogene Ltd.
Select your edition
All financial news and data tailored to specific country editions
